Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA), up to 75% of JIA patients in recent registries have used MTX at some time ...
Biologic therapy reduces TMJ inflammation in children with juvenile arthritis, according to a new study. Findings show ...
The patient developed juvenile idiopathic arthritis at the age of 14 years ... Before tocilizumab therapy began, the patient received methotrexate 15 mg per week and prednisolone 10 mg daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback